Recent studies have shown that there is a high frequency of the variants in genes, such as TP53 (Tumor Protein P53), IDH1 [Isocitrate Dehydrogenase (NADP (+)) 1] and ATRX (Alpha Thalassemia/Mental Retardation Syndrome X-Linked) in younger patients with glioma, and that these variants have an age-dependent prognostic role, such as ATRX variants in patients with low-grade glioma who have shorter survival rate than adult patients do [125,126,127,128]. This evidence concerns the gene TP53 and central nervous system cancer.